Replies to post #319999 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

“Lastly, the manufacturing of Brilacidin intravenous (IV) drug product is expected to produce an amount in excess of what is estimated to be required for the Company’s planned Phase 2 clinical trial, allowing for extra IV drug product to support potential additional COVID-19 clinical testing.”

Hint hint friends.

[humpback]

Isn’t this basically identical to the 8/4 news release?